Join us, in partnership with OriGene, for an exclusive look at the next frontier in cancer immunotherapy: engineered natural killer (NK) cells. This webinar will explore cutting-edge advancements in CAR NK cell therapy. Learn how genetic engineering and cytokine support are enhancing NK cell efficacy, leading to superior tumor control and prolonged survival in preclinical models.
Sunil Acharya, PhD, is a graduate of the MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, where he earned his doctoral degree in cancer biology. Currently serving as a Principal Research Scientist in the laboratory of Dr. Katy Rezvani at MD Anderson Cancer Center, his primary research focus lies in advancing cellular therapy, particularly exploring the potential of Natural Killer (NK) cells as therapeutic agents. He leads the preclinical studies of CD70 CAR NK project which has progressed to a Phase I/II clinical trial targeting both hematologic and solid cancers.
